Nightstar Therapeutics to Participate in BMO Prescriptions for Success Healthcare Conference
07 December 2017 - 10:30PM
YASTEST
LEXINGTON, Mass. and LONDON, Dec. 07,
2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE),
a clinical-stage gene therapy company developing treatments for
rare inherited retinal diseases, today announced that the company
will participate in a fireside chat at the BMO Capital Markets
Prescriptions for Success Healthcare Conference on Thursday, Dec.
14, 2017 at 9:00 a.m. ET in New York City.
To access the live webcast, please
visit ir.nightstartx.com. A replay of the webcast will be available
on the Nightstar website for 60 days following the conference.
About Nightstar
Nightstar is a leading clinical-stage gene therapy
company focused on developing and commercializing novel one-time
treatments for patients suffering from rare inherited retinal
diseases that would otherwise progress to blindness. Nightstar's
lead product candidate, NSR-REP1, is being developed as a treatment
for patients with choroideremia, a rare, degenerative, genetic
retinal disorder that has no current treatments and affects
approximately one in every 50,000 people. Positive results from a
Phase 1/2 trial of NSR-REP1 were published in The
Lancet in 2014 and in The New England Journal of
Medicine in 2016. Nightstar plans to commence a Phase 3
registrational trial of NSR-REP1 for choroideremia at sites in the
United States, Europe and Canada in the first half of 2018.
Nightstar's second product candidate, NSR-RPGR, is currently being
evaluated in a Phase 1/2 clinical trial for the treatment of
patients with X-linked retinitis pigmentosa, an inherited X-linked
recessive retinal disease that affects approximately one in every
40,000 people.
For more information about Nightstar or its
clinical trials, please visit www.nightstartx.com.
Forward-Looking
Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including, but not limited to: statements about
our plans to develop and commercialize our product candidates, our
planned clinical trials for NSR-REP1 and NSR-RPGR, the clinical
utility of our product candidates, the prevalence of patient
populations for our targeted indications, and the utility of prior
preclinical and clinical data in determining future clinical
results . These forward-looking statements are based on
management's current expectations of future events and are subject
to a number of involve substantial known and unknown risks,
uncertainties and other factors that may cause our actual results,
levels of activity, performance or achievements to be materially
different from the information expressed or implied by these
forward-looking statements, including the risks and uncertainties
set forth in the "Risk Factors" section of our prospectus filed
pursuant to Rule 424(b)(4) under the U.S. Securities Act of 1933,
as amended, on September 28, 2017, and subsequent reports that we
file with the U.S. Securities and Exchange Commission. We may not
actually achieve the plans, intentions or expectations disclosed in
our forward-looking statements, and you should not place undue
reliance on our forward-looking statements. Actual results or
events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements we make.
The forward-looking statements in this press release represent our
views as of the date hereof. We anticipate that subsequent events
and developments will cause our views to change. However, while we
may elect to update these forward-looking statements at some point
in the future, we have no current intention of doing so except to
the extent required by applicable law. You should, therefore, not
rely on these forward-looking statements as representing our views
as of any date subsequent to the date of this press release.
Contact:
Senthil Sundaram, Chief Financial
Officer
investors@nightstartx.com
Alicia Davis, THRUST IR
910-620-3302
alicia@thrustir.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Nightstar Therapeutics via Globenewswire
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Jul 2023 to Jul 2024